Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
about
Next-generation prognostic assessment for diffuse large B-cell lymphomaTreatment of diffuse large B cell lymphomaEvolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent updateNovel CD20 monoclonal antibodies for lymphoma therapyMature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Is there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma? A systematic review with meta-analysis.Antibody Therapies in Cancer.My treatment approach to patients with diffuse large B-cell lymphoma.Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma--a meta-analysis of randomized controlled trials.A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaEpstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis.Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis.Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphomaCentral nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trialGenome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphomaSignificant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DMediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association.Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma.ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.Accelerated therapeutic progress in diffuse large B cell lymphoma.Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review.The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project.Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.Adolescent and young adult non-Hodgkin lymphoma.
P2860
Q26796428-C58FB1A6-C309-4C15-B432-5564F96C85AFQ27006062-C6ED6FEC-4223-45B6-88BF-4182DB5F2265Q28078869-85B8230A-5B1C-450E-B688-D987913019FBQ28390112-F089C901-2CCB-46CE-9C8F-60BD1AAE070EQ30240133-E95E3AFE-5252-4082-AF86-5025A882014DQ31072157-FC9E947D-8CE0-490C-903B-15DD8C0B6EECQ31104000-166813EE-A240-43AF-A8FB-F1772079328CQ34251964-7E500BCD-32C0-481D-9CD2-49F66042D998Q34332888-B0C073E0-5887-4C6C-990F-3C7D6E0BA62BQ35236068-84883198-17BC-4157-B958-DF4BF4169F40Q35638549-45133145-FBD3-47F0-BF00-FC3EBC265FAFQ35678403-D454E9EE-A6CD-4F04-B783-3577FFF97C9AQ35723777-D9F28595-7647-4A58-B1CD-C3378818D746Q36411549-9BD23155-40A7-4CA1-B4CB-A58F4E43E3ADQ36413919-68C5E08D-B108-4C66-9C62-8078CEE9F2D0Q36710788-A32D5AF7-C743-42D7-9171-ADA3F40D7F1DQ36859222-60D16617-938A-495D-9B4F-0AE1C7CE400BQ36934345-2C648C29-A6CD-42E8-AF9F-F608B4B697C2Q37224921-C30DA983-16F6-4721-9620-8E5B642557C7Q37473480-F2C80E8B-91C6-460B-9479-D3041F71D00BQ37555826-E7A88DC2-9046-4D74-91E9-0458D9338CF8Q37618814-9C096B0F-B7E0-4CD8-AFA6-B952C8CFCC57Q37662238-4E8B7DE0-E7CB-4D51-A9A3-D028ABC2652EQ37731964-BAE50AC4-DD98-4C64-8AE9-281464D33E56Q38061883-567592C4-9851-407C-90C2-8505D24545E9Q38161760-9877EF5C-4245-4D73-A62D-5C4A95F56759Q38167036-7F3EBF3F-E8DD-4ED3-9273-A4347027345DQ38174498-2CD21ADB-21C6-4FBC-A523-A83EC16219EBQ38179500-7A5D3CDE-CDA0-4E36-98FF-63952AE74E52Q38190105-93CC87E6-4D45-40DD-9F38-64A90FC976CCQ38270640-1E32F8BC-2412-44EE-A35D-47BC8A10E5CDQ38391516-A7B32CFC-FDFA-4E0A-A4C4-D590D9FBB448Q38394272-9175D124-C20B-418A-8B7F-F7007D6A7AEBQ38465823-FD1FE844-B26A-40F8-8E7C-690193C386ABQ38565503-1EC508E3-1744-4073-B24F-A2497306CFC8Q38629758-08EF1383-5806-4F81-A721-DAD057ED1C2CQ38688797-12DCDF6D-1E6D-4F67-81D7-59D7872B9280Q38711166-683842F8-CC2D-48FE-AC2D-A71075FBB911Q38764010-238644D9-C0CD-43A5-A860-5FCA54DE35A4Q38806478-5564D70C-9ED8-46E4-A6A3-12481D1A450A
P2860
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Intensified chemotherapy with ...... abel randomised phase 3 trial.
@en
Intensified chemotherapy with ...... diffuse large B-cell lymphoma
@nl
type
label
Intensified chemotherapy with ...... abel randomised phase 3 trial.
@en
Intensified chemotherapy with ...... diffuse large B-cell lymphoma
@nl
prefLabel
Intensified chemotherapy with ...... abel randomised phase 3 trial.
@en
Intensified chemotherapy with ...... diffuse large B-cell lymphoma
@nl
P2093
P1433
P1476
Intensified chemotherapy with ...... label randomised phase 3 trial
@en
P2093
André Bosly
Bernadette Corront
Bertrand Coiffier
Catherine Thiéblemont
Christian Récher
Christophe Bonnet
Christophe Fermé
Christophe Fruchart
Corinne Haioun
Danielle Canioni
P304
P356
10.1016/S0140-6736(11)61040-4
P407
P577
2011-11-01T00:00:00Z